Investigational drug · Phase 3
TQB3616
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
15
Any phase or sponsor naming "TQB3616"
First trial start
2022
Jul 1, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TQB3616", any sponsor or status.
Conditions studied
As listed on its trial records.
- Breast Cancer
- Metastatic Breast Cancer
- Recurrent Breast Cancer
- Advanced Malignancies
- HR-positive, HER2-negative Breast Neoplasms
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "TQB3616" as an intervention, largest first.
- Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast CancerPivotal-lookingActive, not recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05780567 · 1,946 participants (planned) · Start Mar 30, 2023 · Primary completion Dec 2026
Drug: TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen; Placebo capsules, Letrozole, Anastrozole, Tamoxifen · For: Breast Cancer
Sites: Beijing, China; Guangzhou, China; Suining, China
- To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast CancerPivotal-lookingActive, not recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05365178 · 432 participants · Start Jul 1, 2022 · Primary completion Jul 2, 2025
Drug: TQB3616 capsule; Placebo and 1 more · For: HR-positive, HER2-negative Breast Neoplasms
Sites: Bengbu, China; Wuhu, China; Beijing, China · 88 sites in all
- TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical TrailPivotal-lookingCompleted
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05375461 · 293 participants · Start Mar 18, 2022 · Primary completion Jan 16, 2024
Drug: TQB3616 capsules; TQB3616-matching placebo and 1 more · For: HR-positive,HER2-negative in Advanced Breast Cancer
Sites: Beijing, China · 2 sites in all
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06202261 · 154 participants (planned) · Start Apr 13, 2023 · Primary completion Dec 2026
Drug: TQB2930 for injection; Paclitaxel for injection (albumin-bound) and 6 more · For: Metastatic Breast Cancer; Recurrent Breast Cancer; Advanced Malignancies
Sites: Chongqing, China; Harbin, China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04796623 · 122 participants · Start Feb 4, 2021 · Primary completion May 24, 2024
Drug: TQB3616 capsules; Fulvestrant injection · For: HR-positive, HER2-negative Advanced Breast Cancer
Sites: Beijing, China; Chongqing, China; Lanzhou, China · 17 sites in all
Peking UniversityAcademic, hospital or other
NCT05139082 · 60 participants (planned) · Start Nov 24, 2021 · Primary completion Oct 1, 2023
Drug: TQB3616 capsules+ TQB2450 injection · For: Digestive System Tumors
Sites: Beijing, China
- Drug-Drug Interaction (DDI) Study for TQB3616Status unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06662773 · 40 participants (planned) · Start Nov 2024 · Primary completion Mar 2025
Drug: TQB3616 capsule + itraconazole; TQB3616 capsule + rifampicin · For: Healthy
Sites: Beijing, China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT03850873 · 40 participants · Start May 20, 2019 · Primary completion Sep 23, 2021
Drug: TQB3616 · For: Advanced Breast Cancer
Sites: Beijing, China; Shijiazhuang, China; Zhengzhou, China · 4 sites in all
- Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast CancerActive, not recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06702618 · 33 participants (planned) · Start Feb 20, 2025 · Primary completion Jun 2026
Drug: TQB3616 capsule+Fulvestrant Injection · For: Breast Cancer
Sites: Bengbu, China; Jiangmen, China; Xingtai, China · 13 sites in all
- TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate CancerStatus unknown
West China HospitalAcademic, hospital or other
NCT05156450 · 30 participants (planned) · Start Jan 1, 2022 · Primary completion Oct 1, 2023
Drug: TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone · For: Prostatic Neoplasms, Castration-Resistant; Drug Therapy, Combination
Sites: Chengdu, China
Newest research
PubMed records naming it or its code names, newest first.
- Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial.
Yin Y, Zhang Q, Sun T, et al. · Signal Transduct Target Ther 2025
- CDK4/6 Inhibitor Can Improve Niraparib Sensitivity and Reverse Acquired Drug Resistance Through Endonuclease G Nuclear Translocation in BRCA Wild-Type Ovarian Cancer: A Vitro Study.
Zhou T, Jiang Y, Che X, et al. · BJOG 2025
- The food effect on the pharmacokinetics of TQB3616 capsule in Chinse healthy subjects: a randomized, open-label, single-center, two-period, two-sequence crossover phase I clinical trial.
Dai J, Zhou Y, Zhang L, et al. · Front Pharmacol 2025
- TRIM4 modulates the ubiquitin-mediated degradation of hnRNPDL and weakens sensitivity to CDK4/6 inhibitor in ovarian cancer.
Che X, Guan X, Ruan Y, et al. · Front Med 2025
- Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor.
Xu Z, Liu Y, Song B, et al. · Bioorg Med Chem Lett 2024
- The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models [Letter].
Wardoyo S, Fadillah MA, Hamtini · Breast Cancer (Dove Med Press) 2023
Also in development for Breast Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.